ORTHO RANKS NO. 1 IN CUSTOMER SATISFACTION FOR 5 YEARS IN A ROW
Company receives top customer rating in the 2022 IMV ServiceTrak™ Awards SAN DIEGO, July 26, 2022 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ: QDEL) ("QuidelOrtho") announced today that its subsidiary, Ortho Clinical Diagnostics, a leading provider of in vitro diagnostics solutions and services to hospitals, clinical laboratories and blood banks around the world, has earned the No. 1 ranking in the diagnostics...
Vela Diagnostics Develops PCR-based Test for Detecting Monkeypox Virus
SINGAPORE, July 26, 2022 /PRNewswire/ -- Vela Diagnostics announced that it has developed a PCR test kit to detect the monkeypox virus (MPXV), for research use only (RUO). The ViroKey® MPXV PCR Test allows for the prompt, in vitro detection of MPXV DNA from human skin lesion specimens. It is compatible with common real-time PCR cyclers, such as the Rotor-Gene...
Menarini Silicon Biosystems and DIESSE announced strategic partnership to distribute CHORUS TRIO in North America
The commercial agreement to promote and sell CHORUS TRIO immunometric assay solutions in the U.S. Market was announced jointly by the two companies during the AACC Annual Scientific Meeting & Clinical Lab Expo in Chicago. CHICAGO, July 26, 2022 /PRNewswire/ -- Menarini Silicon Biosystems Inc, a US company part of the Menarini Group...
Gracell Biotechnologies to Participate in BTIG 2022 Biotechnology Conference
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, July 26, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in BTIG 2022 Hybrid Biotechnology...
Novavax Announces Expanded Approval of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 through 17 in Japan
Nuvaxovid™ is the first protein-based COVID-19 vaccine approved for use in adolescents in Japan GAITHERSBURG, Md., July 26, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine received expanded manufacturing and...
Motex Showcases Award-Winning Face Masks in Miami at FIME 2022
CHANGHUA, Taiwan, July 26, 2022 /PRNewswire/ -- Motex Healthcare Corp., the world's largest medical grade mask producer and certified by the Guinness World Records, is featuring their latest award-winning face masks at this year's FIME 2022 in Miami Beach, USA. From July 27 to July 29, the company will exhibit their most innovative face mask based on the concept of...
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Provisional Registration in Australia for Use in Adolescents Aged 12 Through 17
Nuvaxovid™ is the first protein-based COVID-19 vaccine available for use in adolescents aged 12 through 17 in Australia GAITHERSBURG, Md., July 26, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the Australian Therapeutic Goods Agency (TGA)...
Henlius HANQUYOU Received TGA Approval in Australia
SHANGHAI, July 26, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the company's business partner Cipla Limited ("Cipla") has received the relevant registration certificates from the Therapeutic Goods Administration of Australia ("TGA") for the approval of Henlius' self-developed and manufactured HANQUYOU (trastuzumab, trade name in Europe: Zercepac®) with the specification of 150mg/vial in Australia under the trade...
Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study participants in HKU Clinical Trials Centre
All 16 healthy normal volunteers (HNVs) were dosed and no serious adverse event was reported The NTM-001 Phase I clinical study is expected to be completed by the end of 2022 SHANGHAI, July 26, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces the completion of dosing for all HNVs in the Phase I clinical study of its novel...
Sirnaomics Receives IND Clearance from the “Taiwan Ministry of Health and Welfare” for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment
GAITHERSBURG, Md. and SUZHOU, China, July 26, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Company has received regulatory clearance from the "Taiwan Ministry of Health and Welfare (TMHW)" of its Investigational New Drug (IND) application to commence a Phase...
